Fragility Index and Fragility Quotient in Randomized Controlled Trials on Corticosteroids in ARDS Due to COVID-19 and Non-COVID-19 Etiology.
Maria VargasAnnachiara MarraPasquale BuonannoAntonio CovielloCarmine IacovazzoGiuseppe ServilloPublished in: Journal of clinical medicine (2021)
Thirteen RCTs were included in the analysis; five of them were conducted in COVID-19 ARDS, including 7692 patients, while 8 RCTS were performed in non-COVID ARDS with 1091 patients evaluated. Three out of eight RCTs in ARDS had a FI > 0 while 2 RCTs out of five in COVID-19 had FI > 0. The median of FI for ARDS was 0.625 (0.47) while the median of FQ was 0.03 (0.014). The median of FI for COVID-19 was 6 (2) while the median of FQ was 0.059 (0.055). In this systematic review, we found that FI and FQ of RCTs evaluating the use of corticosteroids in ARDS and COVID-19 were low.
Keyphrases
- coronavirus disease
- sars cov
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- systematic review
- mechanical ventilation
- end stage renal disease
- ejection fraction
- newly diagnosed
- randomized controlled trial
- respiratory syndrome coronavirus
- chronic kidney disease
- prognostic factors
- intensive care unit
- clinical trial
- patient reported outcomes